Prolonging the delivery of influenza virus vaccine improves the quantity and quality of the induced immune responses in mice

Influenza vaccines play a vital role in protecting individuals from influenza virus infection and severe illness. However, current influenza vaccines have suboptimal efficacy, which is further reduced in cases where the vaccine strains do not match the circulating strains. One strategy to enhance the efficacy of influenza vaccines is by extended antigen delivery, thereby mimicking the antigen kinetics of a natural infection. Prolonging antigen availability was shown to quantitatively enhance influenza virus-specific immune responses but how it affects the quality of the induced immune response is unknown. Therefore, the current study aimed to investigate whether prolongation of the delivery of influenza vaccine improves the quality of the induced immune responses over that induced by prime-boost immunization. To study this, mice were given daily doses of whole inactivated influenza virus vaccine for periods of 14, 21, or 28 days; the control group received prime-boost immunization with a 28 days interval. Our data show that the highest levels of cellular and humoral immune responses were induced by 28 days of extended antigen delivery, followed by 21, and 14 days of delivery, and prime-boost immunization. Moreover, prolonging vaccine delivery also improved the quality of the induced antibody response, as indicated by higher level of high avidity antibodies, a balanced IgG subclass profile, and a higher level of cross-reactive antibodies. Overall, our findings contribute to a better understanding of the immune response to influenza vaccination and have important implications for the design and development of future slow-release influenza vaccines.

[1]  J. C. Love,et al.  Low protease activity in B cell follicles promotes retention of intact antigens after immunization , 2023, Science.

[2]  P. Bieniasz,et al.  Molecular fate-mapping of serum antibody responses to repeat immunization , 2023, Nature.

[3]  D. van Baarle,et al.  A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets , 2022, bioRxiv.

[4]  S. Sambhara,et al.  Progress towards the Development of a Universal Influenza Vaccine , 2022, Viruses.

[5]  M. Meyer-Hermann,et al.  Investigating the Mechanism of Germinal Center Shutdown , 2022, Frontiers in Immunology.

[6]  Eric A. Appel,et al.  Sustained delivery approaches to improving adaptive immune responses. , 2022, Advanced drug delivery reviews.

[7]  E. Zoetendal,et al.  The level and distribution of methyl-esters influence the impact of pectin on intestinal T cells, microbiota, and Ahr activation. , 2022, Carbohydrate polymers.

[8]  Jordan A. Stinson,et al.  Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles. , 2021, Vaccine.

[9]  Eric A. Appel,et al.  Modulation of injectable hydrogel properties for slow co‐delivery of influenza subunit vaccine components enhance the potency of humoral immunity , 2021, Journal of biomedical materials research. Part A.

[10]  Eric A. Appel,et al.  Prolonged Codelivery of Hemagglutinin and a TLR7/8 Agonist in a Supramolecular Polymer–Nanoparticle Hydrogel Enhances Potency and Breadth of Influenza Vaccination , 2021, ACS biomaterials science & engineering.

[11]  D. Irvine,et al.  Controlling timing and location in vaccines , 2020, Advanced Drug Delivery Reviews.

[12]  A. Huckriede,et al.  Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement. , 2020, Vaccine.

[13]  M. Prausnitz,et al.  Extended delivery of vaccines to the skin improves immune responses , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[14]  F. Krammer.  The human antibody response to influenza A virus infection and vaccination , 2019, Nature Reviews Immunology.

[15]  Daniel W. Kulp,et al.  Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance , 2018, Cell.

[16]  W. Hinrichs,et al.  Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge , 2018, Journal of Controlled Release.

[17]  Gavin J. D. Smith,et al.  Influenza , 2018, Nature Reviews Disease Primers.

[18]  L. Boon,et al.  Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines , 2018, bioRxiv.

[19]  Carrie Reed,et al.  Seasonal Incidence of Symptomatic Influenza in the United States , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  David J. Topham,et al.  Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies , 2018, Cell.

[21]  David Putnam,et al.  A single dose and long lasting vaccine against pandemic influenza through the controlled release of a heterospecies tandem M2 sequence embedded within detoxified bacterial outer membrane vesicles. , 2017, Vaccine.

[22]  A. Monto,et al.  2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  G. Victora,et al.  Germinal Center B Cell Dynamics. , 2016, Immunity.

[24]  R. Varadarajan,et al.  Stalking influenza by vaccination with pre-fusion headless HA mini-stem , 2016, Scientific Reports.

[25]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[26]  Antoine M. van Oijen,et al.  Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization , 2013, PloS one.

[27]  P. Palese,et al.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. , 2013, Journal of visualized experiments : JoVE.

[28]  J. Wilschut,et al.  Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100 , 2012, PloS one.

[29]  J. Wrammert,et al.  Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses , 2012, Proceedings of the National Academy of Sciences.

[30]  W. Hinrichs,et al.  Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. , 2011, Vaccine.

[31]  N. Petrovsky,et al.  Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations , 2011, The Journal of general virology.

[32]  M. Severa,et al.  Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling , 2008, PLoS pathogens.

[33]  J. Wilschut,et al.  Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. , 2008, Vaccine.

[34]  K. Murali‐Krishna,et al.  CD8 T Cell Expansion and Memory Differentiation Are Facilitated by Simultaneous and Sustained Exposure to Antigenic and Inflammatory Milieu1 , 2008, The Journal of Immunology.

[35]  K. Schwarz,et al.  Long‐lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation , 2006, European journal of immunology.

[36]  Deborah M. Brown,et al.  Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation , 2005, The Journal of experimental medicine.

[37]  R. Cox,et al.  Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice , 2005, Scandinavian journal of immunology.

[38]  C. Benoist,et al.  Antigen persistence is required throughout the expansion phase of a CD4+ T cell response , 2005, The Journal of experimental medicine.

[39]  R. Cox,et al.  Comparison of the humoral immune response to split and whole virus vaccines in mice , 2004 .

[40]  T. Storni,et al.  Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction , 2003, The Journal of Immunology.

[41]  K. Toellner,et al.  T Helper 1 (Th1) and Th2 Characteristics Start to Develop During T Cell Priming and Are Associated with an Immediate Ability to Induce Immunoglobulin Class Switching , 1998, The Journal of experimental medicine.